On April 1, 2024, iBio, Inc closed the transaction. The company issued 2,701,315 shares of the Company?s common stock, par value $0.001, pre-funded warrants to purchase up to 2,585,963 shares of the Common Stock at an exercise price of $0.0001 per share, and Series E Common Stock purchase warrants to purchase up to 5,287,278 shares of the Company?s Common Stock at an exercise price of $2.64 per share for gross proceeds of approximately $15,066,156.337. The company will issue securities pursuant to exemption provided under Regulation D from 8 investors.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.03 USD | +9.73% | +18.02% | +48.18% |
1st Jan change | Capi. | |
---|---|---|
+48.18% | 15.93M | |
+29.68% | 699B | |
+25.07% | 571B | |
-4.35% | 364B | |
+17.65% | 326B | |
+3.77% | 286B | |
+14.68% | 236B | |
+4.71% | 198B | |
-12.43% | 194B | |
-3.79% | 154B |
- Stock Market
- Equities
- IBIO Stock
- News iBio, Inc.
- IBio, Inc. announced that it has received $15.066157 million in funding from ADAR1 Capital Management, LLC, Lynx1 Capital Management LP, Ikarian Capital, LLC and other investors